Abstract
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of cetuximab (Merck Serono) to submit evidence for the clinical and cost effectiveness of cetuximab in combination with platinum-based chemotherapy (CTX) for the treatment of patients with recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN) according to the Institute’s Single Technology Appraisal (STA) process. The Liverpool Reviews and Implementation Group at the University of Liverpool was commissioned to act as the Evidence Review Group (ERG).
This article summarizes the ERG’s review of the evidence submitted by the manufacturer. A summary of the Appraisal Committee (AC) decision is provided. The ERG reviewed the clinical evidence in accordance with the decision problem defined by NICE. The analysis of the submitted model assessed the appropriateness of the manufacturer’s approach to modelling the decision problem, the reliability of model implementation and the extent of conformity to published standards and prevailing norms of practice within the health economics modelling community. Particular attention was paid to issues likely to impact substantially on the base-case cost-effectiveness results.
Clinical-effectiveness evidence was derived from a single randomized controlled trial (RCT). Results presented for clinical outcomes were strongly supportive of benefits resulting from the use of cetuximab. Cetuximab + platinum-based CTX with 5 fluorouracil (5-FU) extended median overall survival (OS) from 7.4 months in the CTX group to 10.1 months in the cetuximab + CTX group. Median progression-free survival rose from 3.3 months to 5.6 months, best overall response to therapy increased from 19.5% to 35.6%, disease control rate rose from 60% to 81.1% and median time to treatment failure was 4.8 months compared with 3.0 months.
Exploratory subgroup analyses indicated significant OS benefits in 11 of 16 pre-planned analyses.
The ERG identified a number of issues relating to the clinical-effectiveness results: consideration was limited to first-line use of cetuximab; patients in the trial were younger and fitter than those presenting in UK clinical practice; there was no evidence of survival advantage for patients with metastatic disease; there was no evidence of effectiveness in patients not cetuximab-naive; and the quality-of-life data were poor.
The submitted incremental cost-effectiveness ratio was considerably above the NICE threshold. The ERG questioned the submitted economic model on a number of grounds: the rationale for creating an economic model rather than direct analysis of trial data; the use of Weibull functions for survival models; inaccurate CTX costs; selection of health state utilities; inaccurate unit costs; and lack of mid-cycle correction. After amending the model, the ERG considered the use of cetuximab to be not cost effective for NICE at any price.
The AC concluded that cetuximab in combination with platinum-based CTX should not be recommended for the treatment of patients with recurrent and/or metastatic SCCHN. Patients already receiving this treatment for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop. This was the first appraisal to consider the end-of-life medicines criteria introduced by NICE in January 2009.
Similar content being viewed by others
Bibliografia
National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. London: NICE, 2006 Sep. Disponibile sul sito: http://www.nice.org.uk/media/8DE/74/STA_Process_Guide.pdf (Accesso del 10/06/09)
National Institute for Health and Clinical Excellence. Head and neck cancer (squamous cell carcinoma) — cetuximab. London: NICE. Disponibile sul sito: http://www.nice.org.uk/guidance/index.jsp?action=byId&o=11987&history=t (Accesso del 2/02/10)
Office of National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2005, England [series MB1 no. 36]. Norwich: Office of National Statistics, 2008. Disponibile sul sito: http://www.statistics.gov.uk/downloads/theme_health/MB1_36/MB1_No36_2005.pdf (Accesso del 1/10/08)
Welsh Cancer Intelligence and Surveillance Unit. Cancer incidence in Wales 2002–2006 [WCISU annual publication no. SA8/01]. Disponibile sul sito: http://www.wales.nhs.uk/sites3/Documents/242/incpub2006%5F31Jan08.pdf (Accesso del 1/10/08)
Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Canc Metastasis Rev 2005; 24(1): 9–17
National Institute for Health and Clinical Excellence. Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck [NICE technology appraisal guidance 145]. London: NICE, 2008. Disponibile sul sito: http://www.nice.org.uk/guidance/index.jsp?action=download&o=41000 (Accesso del 1/10/08)
European Medicines Agency. Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for erbitux. London: European Medicines Agency, 2008. Disponibile sul sito: http://www.emea.europa.eu/pdfs/human/opinion/Erbitux_56158008en.pdf (Accesso del 10/06/09)
National Institute for Health and Clinical Excellence. Merck Serono Ltd. Single technology appraisal submission: Er-bitux_ (Cetuximab) for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Disponibile sul sito: http://www.nice.org.uk/nicemedia/pdf/MerckSerono.pdf (Accesso del 10/06/09)
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008 Sept; 359: 1116–27
Merck Serono Ltd. Single technology appraisal submission: Erbitux_ (Cetuximab) for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Disponibile sul sito: http://www.nice.org.uk/nicemedia/pdf/MerckSerono.pdf (Accesso del 10/06/09)
Kind P. Measuring the value of quality of life in cancer: an index based on EORTC QLQC-30 [abstract]. J Clin Oncol 2005; 23(16S): 6013
Sacco JJ, Botten J, Macbeth F, et al. The average body surface area of adult cancer patients in the UK: a multi-centre retrospective study. PloS ONE 2010; 5(1): e8933
National Institute for Health and Clinical Excellence. Final appraisal determination: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck. London: NICE, 2009 Apr. Disponibile sul sito: http://www.nice.org.uk/nicemedia/pdf/SquamousCellCarcinomaCetuximabFAD.pdf (Accesso del 10/06/09)
National Institute for Health and Clinical Excellence. Appraising life-extending end of life treatments. London: NICE, 2009 Jan. Disponibile sul sito: http://www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf (Accesso del 10/06/09)
Author information
Authors and Affiliations
Corresponding author
Additional information
Traduzione dell’articolo Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. A NICE Single Technology Appraisal. Pharmacoeconomics 2010; 28 (6): 439–448.
Rights and permissions
About this article
Cite this article
Bagust, A., Greenhalgh, J., Boland, A. et al. Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE. Pharmacoeconomics-Ital-Res-Articles 13, 101–110 (2011). https://doi.org/10.1007/BF03320687
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03320687